Hepion raises $400K in stock-and-warrant sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
Hepion Pharmaceuticals, Inc. (HEPA) entered into securities purchase agreements with certain accredited investors for a private placement of 8,000,000 shares of common stock and warrants to purchase 8,000,000 shares of common stock at an offering price of $0.05 per share, for gross proceeds of $400,000. The warrants are exercisable at an exercise price of $0.06 per share for a term of five years from issuance. The securities are being issued in an unregistered private offering relying on Section 4(a)(2) of the Securities Act and/or Rule 506(b) of Regulation D, and may not be offered or sold in the United States without registration or an applicable exemption. The agreements include customary representations, warranties, conditions to closing, indemnification obligations, and termination provisions.
8-K Event Classification
3 items: 1.01, 3.02, 9.01
3 items
Item 1.01
Entry into a Material Definitive Agreement
Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 3.02
Unregistered Sales of Equity Securities
Securities
The company sold equity securities in a private placement or other unregistered transaction.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Common stock offered: 8,000,000 shares
Warrants offered: 8,000,000 warrants
Offering price per share: $0.05 per share
+3 more
6 metrics
Common stock offered
8,000,000 shares
Shares of common stock in the private placement offering
Warrants offered
8,000,000 warrants
Warrants to purchase common stock issued with the shares
Offering price per share
$0.05 per share
Price at which common stock is sold in the offering
Gross proceeds
$400,000
Aggregate gross proceeds from the private placement
Warrant exercise price
$0.06 per share
Exercise price of the warrants issued in the offering
Warrant term
5 years
Period during which the warrants are exercisable from issuance
Key Terms
private placement offering, accredited investors, Section 4(a)(2), Rule 506(b) of Regulation D, +1 more
5 terms
private placement offering financial
"to sell and issue to the Investors in a private placement offering"
A private placement offering is when a company sells its stock or bonds directly to a small group of investors instead of offering them to the general public. This allows the company to raise money quickly and privately, often for specific projects or needs, without going through a public stock exchange.
accredited investors financial
"agreements with certain accredited investors (the “Investors”)"
Accredited investors are individuals or entities considered to have enough financial knowledge and resources to understand and handle more complex and risky investments. They are often allowed to participate in private investment opportunities that are not available to the general public, similar to how experienced players might access exclusive clubs or events. This status helps ensure that investors can manage potential risks and rewards appropriately.
Section 4(a)(2) regulatory
"offered in reliance upon the exemption from the registration requirement ... Section 4(a)(2)"
Section 4(a)(2) is a part of U.S. securities laws that allows companies to sell their stock directly to certain investors without registering the sale with regulators. This process is often used for private placements, making it easier and faster for companies to raise money from knowledgeable or institutional investors. It matters to investors because it provides an alternative way to buy shares, often with fewer disclosures and lower costs.
Rule 506(b) of Regulation D regulatory
"and/or Rule 506(b) of Regulation D promulgated thereunder"
Rule 506(b) of Regulation D is a set of rules that allows companies to raise money from investors without having to register with the government, as long as they follow certain guidelines. It lets companies offer securities to a limited number of investors, often trusted or experienced ones, making it easier and quicker to raise funds compared to traditional methods. This rule matters to investors because it provides access to private investment opportunities that are generally less regulated but still require careful consideration.
indemnification obligations financial
"contain customary representations, warranties ... indemnification obligations of the Company"
A company's indemnification obligations are promises it has made to cover certain losses, legal costs, or damages that another party might suffer because of the company’s actions or events tied to a deal. Think of it like a guarantee or built-in insurance: if something goes wrong, the company must step in and pay. For investors this matters because these potential payouts create contingent liabilities that can reduce cash, raise legal exposure, and affect a company’s value and risk profile.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What financing transaction did HEPA announce on August 25, 2026?
Hepion Pharmaceuticals, Inc. entered into agreements for a private placement of 8,000,000 shares of common stock and warrants for 8,000,000 shares at $0.05 per share, for $400,000 in gross proceeds, with warrants exercisable at $0.06 for five years.
How much capital is Hepion Pharmaceuticals (HEPA) raising in this private placement?
Hepion is raising $400,000 in gross proceeds through the sale of 8,000,000 shares of common stock and related warrants at an offering price of $0.05 per share in a private placement with accredited investors.
What are the key terms of the Hepion (HEPA) warrants issued in this deal?
The warrants give holders the right to purchase up to 8,000,000 shares of common stock at an exercise price of $0.06 per share, and are exercisable for five years from the date of issuance, according to Hepion’s disclosure.
Is Hepion’s August 2026 securities offering registered with the SEC?
No. Hepion states that the common stock and warrants have not been registered under the Securities Act and are being offered in reliance on Section 4(a)(2) and/or Rule 506(b) of Regulation D, and applicable state securities laws.
Who is eligible to participate in Hepion’s (HEPA) August 2026 offering?
Hepion entered into securities purchase agreements with accredited investors. The company describes the transaction as a private placement relying on Section 4(a)(2) and/or Rule 506(b) of Regulation D exemptions.
AI-generated analysis. How Rhea-AI works. Not financial advice.
